These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37405278)

  • 1. The effect of lung emptying before the inhalation of aerosol drugs on drug deposition in the respiratory system.
    Farkas Á; Tomisa G; Szénási G; Füri P; Kugler S; Nagy A; Varga J; Horváth A
    Int J Pharm X; 2023 Dec; 6():100192. PubMed ID: 37405278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of exhalation before the inhalation of dry powder aerosol drugs on the breathing parameters, emitted doses and aerosol size distributions.
    Farkas Á; Tomisa G; Kugler S; Nagy A; Vaskó A; Kis E; Szénási G; Gálffy G; Horváth A
    Int J Pharm X; 2023 Dec; 5():100167. PubMed ID: 36824288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
    Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
    Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
    Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
    Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.
    Jókay Á; Farkas Á; Füri P; Horváth A; Tomisa G; Balásházy I
    Eur J Pharm Sci; 2016 Jun; 88():210-8. PubMed ID: 26976481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
    Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
    Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of Airway Deposition of an Aerosol Drug in COPD Patients.
    Farkas Á; Lizal F; Jedelsky J; Elcner J; Horváth A; Jicha M
    Pharmaceutics; 2019 Apr; 11(4):. PubMed ID: 30939795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Small Airways with Inhaled Corticosteroid/Long-Acting Beta Agonist Dry Powder Inhalers: A Functional Respiratory Imaging Study.
    Watz H; Barile S; Guastalla D; Topole E; Cocconi D; Mignot B; Belmans D; Duman D; Poli G; Fabbri LM
    J Aerosol Med Pulm Drug Deliv; 2021 Sep; 34(5):280-292. PubMed ID: 33944614
    [No Abstract]   [Full Text] [Related]  

  • 11. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
    Van Holsbeke C; De Backer J; Vos W; Marshall J
    Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort
    Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G
    Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhalation Profiles Through a Dry Powder Inhaler: Relation Between Inhalation Technique and Spirometric Measures.
    Dorosz A; Urbankowski T; Zieliński K; Michnikowski M; Krenke R; Moskal A
    J Aerosol Med Pulm Drug Deliv; 2021 Dec; 34(6):346-357. PubMed ID: 33877899
    [No Abstract]   [Full Text] [Related]  

  • 15. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
    Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
    Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler
    Farkas Á; Lewis D; Church T; Tweedie A; Mason F; Haddrell AE; Reid JP; Horváth A; Balásházy I
    Int J Pharm; 2017 Nov; 533(1):225-235. PubMed ID: 28941830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.